Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes

Massimo Di Nicola, Marco Milanesi, Michele Magni, Marco Bregni, Carmelo Carlo-Stella, Paolo Longoni, Rosella Tomanin, Fabrizio Ravagnani, Maurizio Scarpa, Craig Jordan, A. Massimo Gianni

Research output: Contribution to journalArticlepeer-review

Abstract

We have evaluated, as a vector for gene transfer into human T lymphocytes, a recombinant adenovirus (rAdMFG-AP) carrying a modified, membrane-exposed, alkaline phosphatase (AP) as reporter gene. CD3+ cells were selected from the buffy coat of healthy donors by the immunomagnetic technique. The positive cell population, comprising 96 ± 2% CD3+ cells, was cultured with clinical-grade cytokine(s) for 3-7 days prior to rAd-MFG-AP transduction and the transgene expression was evaluated 48 hr later by indirect immunofluorescence flow cytometry assay with an anti-alkaline phosphatase antibody. The best efficiency of transduction was achieved on incubation of CD3+ cells with IL-2 plus either IL-12 (AP+ cells, 12 ± 3%) or IL-7 (AP+ cells, 11 ± 3%). To increase further the efficiency of transduction, we have combined LipofectAMINE and rAdMFG-AP with the aim to enhance the uptake of viral particles into the target cells. The percentage of CD3+ cells transduced by rAd-MFG-AP-LipofectAMINE complex was 24 ± 4% (range, 20-35%) after incubation with IL-2 plus IL-7 and 22 ± 4% (range, 18- 32%) after incubation with II-2 plus IL-12. Forty-eight hours after the incubation with rAd-MFG-AP, the transduced T lymphocytes were subjected to fluorescence-activated cell sorting and fractionated into AP+ and AP- cell subpopulations. The AP+ cell fraction, comprising 96.8% of AP+ cells, was evaluated by FACScan analysis for T lymphocyte surface antigens. The immunophenotyping of the transduced T lymphocytes has shown that there was not a particular subtype of T lymphocytes more susceptible to rAd-MFG-AP transduction. In addition, the transgene expression did not modify T lymphocyte functions, as demonstrated by results obtained by cytotoxicity assay before and after rAd-MFG-AP-LipofectAMINE complex transduction. In conclusion, human T lymphocytes can be efficiently transduced, under clinically applicable conditions, by adenovirus-LipofectAMINE complex after 7 days of culture with IL-2 and IL-12 or IL-7.

Original languageEnglish
Pages (from-to)1875-1884
Number of pages10
JournalHuman Gene Therapy
Volume10
Issue number11
DOIs
Publication statusPublished - Jul 20 1999

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes'. Together they form a unique fingerprint.

Cite this